Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: The potential to use resistance data to guide clinical decisions

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 6, 1997, Pages 765-777

  Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

CLINICAL RESEARCH; CROSS RESISTANCE; DISEASE MARKER; DRUG CHOICE; DRUG METABOLISM; DRUG RESISTANCE; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MEDICAL DECISION MAKING; MOLECULAR BIOLOGY; PLASMA; POLYMERASE CHAIN REACTION; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION; VIRAL GENETICS; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0031436702     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.6.765     Document Type: Review

References (116)

1. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P. et al. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-22.
2. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M. & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-6.
3. Mansky, L. M. & Temin, H. M. (1995). Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from fidelity of purified reverse transcriptase. Journal of Virology 69, 5087-94.
4. Schinazi, R. F., Lloyd, R. M., Ramanathan, C. S. & Taylor, E. W. (1994). Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions. Antimicrobial Agents and Chemotherapy 38, 268-74.
5. Coffin, J. M. (1995). HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267, 483-9.
6. Haseltine, W. A. & Wong-Staal, F. (1988). The molecular biology of the AIDS virus. Scientific American 259, 34-42.
7. Saag, M. S., Hahn, B. H., Gibbons, J., Li, Y., Parks, E. S., Parks, W. P. et al. (1988). Extensive variation of human immunodeficiency virus type 1 in vivo. Nature 334, 440-4.
8. Kunzi, M. S. & Groopman, J. E. (1993). Identification of a novel human immunodeficiency virus strain cytopathic to megakaryocytic cells. Blood 81, 3336-42.
9. Connor, R. I. & Ho, D. D. (1994). Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. Journal of Virology 68, 4400-8.
10. Mohri, H., Singh, M. K., Ching, W. T. W. & Ho, D. D. (1993). Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proceedings of the National Academy of Sciences of the USA 90, 25-9.
11. Najera, I., Richman, D. D., Olivares, I., Rojas, J. M., Peinado, M. A., Perucho, M. et al. (1994). Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Research Human Retroviruses 10, 1479-88.
12. Najera, I., Holguin, A., Quinones-Mateu, E., Munoz-Fernandez, M. A., Najera, R., Lopez-Galindez, C. et al. (1995). Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. Journal of Virology 69, 23-31.
13. Frost, S. D. W. & McLean, A. R. (1994). Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 8, 323-32.
14. Kellam, P., Boucher, C. A. B., Tijnagal, J. M. G. H. & Larder, B. A. (1994). Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. Journal of General Virology 75, 341-51.
15. Coffin, J. M. (1992). Genetic diversity and evaluation of retro-viruses. Current Topics in Microbiology and Immunology 176, 143-64.
16. Boucher, C. A., O'Sullivan, E., Mulder, J. W., Ramautarsing, C., Kellam, P., Darby, G. et al. (1992). Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. Journal of Infectious Diseases 165, 105-10.
17. Condra, J. H., Schlief, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C. et al. (1995). Dynamics of acquired HIV-1 clinical resistance to the protease inhibitor MK-639. In Proceedings of the 4th International HIV Drug-resistance Workshop, Sardinia, 1995. Abstract 72.
18. Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C. et al. (1995). In-vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-71.
19. Rooke, R., Tremblay, M., Soudeyns, H., DeStephano, L., Yao, X. J., Fanning, M. et al. (1989). Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 3, 411-15.
20. Albert, J., Wahlberg, J., Lundeberg, J., Cox, S., Sandström, E., Wahren, B. et al. (1992). Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in post-treatment sera. Journal of Virology 66, 5627-30.
21. Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. C. et al. (1995). Evidence for the existence of long-lived genetic reservoirs of HIV-1 in infected patients. In Proceedings of the 4th International HIV Drug-resistance Workshop, Sardinia, 1995. Abstract 82.
22. Gazzard, B. G., Moyle, G. J., Weber, J., Johnson, M., Bingham, J. S., Brettle, R. et al. (1997). British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 349, 1086-92.
23. Stuyver, L., Wyseur, A., Rombout, A., Louwagie, J., Scacrez, T., Verhofstede, C. et al. (1997). Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrobial Agents and Chemotherapy 41, 284-91.
24. Wildemann, B., Haas, J., Ehrhart, K., Wagner, H., Lynen, N. & Storch-Hagenlocher, B. (1993). In-vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1 infected patients both simultaneously in plasma but also between different body compartments such as blood and CSF. Neurology 43, 2659-63.
25. Delassus, S., Cheynier, R. & Wain-Hobson, S. (1992). Non-homogeneous distribution of human immunodeficiency virus type 1 proviruses within the spleen. Journal of Virology 66, 5642-5.
26. Korber, B. T. M., Kunstman, K. J., Patterson, B. K., Furtado, M., McEvilly, M. M., Levy, R. et al. (1994). Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. Journal of Virology 68, 7467-81.
27. Ball, J. K., Holmes, E. C., Whitwell, H. & Desselberger, U. (1994). Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy. Journal of General Virology 75, 67-79.
28. Portegies, P. (1995). HIV-1, the brain, and combination therapy. Lancet 346, 1244-5.
29. Di Stefano, M., Norkrans, G., Chiodi, F., Hagberg, L., Nielsen, C. & Svennerholm, B. (1993). Zidovudine-resistant variants of HIV-1 in brain. Lancet 342, 865.
30. Barry, M., Wild, M., Veal, G., Back, D., Beckenridge, A., Fox, R. et al. (1994). Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 8, F1-F5.
31. Stretcher, B. N., Pesce, A. J., Frame, P. T., Greenberg, K. A. & Stein D. S. (1994). Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 8, 763-9.
32. Dianzani, F., Antonelli, G., Turriziani, O., Riva, E., Simeoni, E., Signoretti, C. et al. (1994). Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Research Human Retroviruses 10, 147-8.
33. Back, D. J., Haggard, P. G., Veal, G. J. & Barry, M. G. (1995). Intracellular phosphorylation interactions between nucleoside analogues. In Proceedings of the 5th European Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen, 1995. Abstract 41, p. 6.
34. Holodniy, M., Katzenstein, D., Mole, L., Winters, M. & Merigan, T. (1996). Human immunodeficiency virus reverse transcriptase Codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing viral phenotype. Journal of Infectious Diseases 174, 854-7.
35. Sylvester, S., Caliendo, A., An, D., Savara, A., Byington, R., Strick, D. et al. (1995). HIV-1 resistance mutations and plasma RNA during ZDV and ddC combination therapy. In Proceedings of the 4th International HIV Drug-resistance Workshop, Sardinia, 1995. Abstract 47.
36. D'Aquila, R. T. (1994). HIV-1 drug resistance: molecular pathogenesis and laboratory monitoring. Clinics in Laboratory Medicine 14, 393-422.
37. Smith, M. S., Koerber, K. L. & Pagano, J. S. (1994). Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. Journal of Infectious Diseases 169, 184-8.
38. Moyle, G. J. (1996). Activity and role of lamivudine in the treatment of adults with human immunodeficiency virus type 1 infection: a review. Expert Opinion on Investigational Drugs 5, 913-24.
39. Havlir, D., Cheeseman, S. H., McLaughlin, M., Murphy, R., Erice, A., Spector, S. A. et al. (1995). High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. Journal of Infectious Diseases 171, 537-45.
40. Japour, A. J., Welles, S., D'Aquila, R. T., Johnson, V. A., Richman, D. D., Coombs, R. W. et al. (1995). Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. Journal of Infectious Diseases 171, 1172-9.
41. D'Aquila, R. T., Johnson, V. A., Welles, S. L., Japour, W. A., Kuritzkes, D. R., DeGruttola, V. et al. (1995). Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Annals of Internal Medicine 122, 401-8.
42. Havlir, D. V., Eastman, S., Gamst, A. & Richman, D. D. (1996). Nevaripine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. Journal of Virology 70, 7894-9.
43. Larder, B. A., Darby, G. & Richman, D. D. (1989). HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-4.
44. Boucher, C. A. B., Tersmette, M., Lange, J. M. A., Kellam, P., de Goede, R. E., Mulder, J. W. et al. (1990). Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 336, 585-90.
45. Lopez-Galindez, C., Rojas, J. M., Najera, R., Richman, D. D. & Perucho, M. (1991). Characterization of genetic variation and 3′-azido-3′-deoxythymidine resistance mutations of HIV by the RNase mismatch cleavage method. Proceedings of the National Academy of Sciences of the USA 88, 4280-4.
46. Larder, B. A., Kellam, P. & Kemp, S. D. (1991). Zidovudine resistance predicted by direct detection of mutants in DNA from HIV-infected lymphocytes. AIDS 5, 137-44.
47. De Jong, M. D., Veenstra, J., Stilianakis, N. I., Schuurman, R., Lange, J. M. A., de Boer, R. J. et al. (1996). Host-parasite dynamics and outgrowth of virus containing a single K7OR amino acid change in reverse transcriptase are responsible for loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proceedings of the National Academy of Sciencies of the USA 93, 9501-6.
48. Mayers, D. L., McCutchan, F. E., Sanders-Buell, E. E., Merritt, L. I., Dilworth, S., Fowler, A. K. et al. (1992). Characterization of HIV isolates arising after prolonged zidovudine therapy. Journal of Acquired Immune Deficiency Syndrome 5, 749-59.
49. St Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M. et al. (1991). Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557-9.
50. Larder, B. A. (1992). 3′Azido-3′deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy 36, 2664-9.
51. Boucher, C. A. B., Cammack, N., Schipper, P., Schuurman, R., Rouse, P., Wainberg, M. A. et al. (1993). High-level resistance to (-)enantiomeric 2′deoxy-3′-thiacytidine (3TC) in vitro is due to one amino acid substitution in the catalytic site of HIV-1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 37, 2231-4.
52. Tisdale, M., Kemp, S. D., Parry, N. R. & Larder, B. A. (1993). Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences of the USA 90, 5653-6.
53. Larder, B. A., Kemp, S. D. & Harrigan, P. R. (1995). Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269, 696-9.
54. Zhang, D., Caliendo, A. M., Eron, J. J., DeVore, K. M., Kaplan, J. C., Hirsch, M. S. et al. (1994). Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 38, 282-7.
55. Larder, B. A., Chesebro, B. & Richman, D. D. (1990). Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrobial Agents and Chemotherapy 34, 436-41.
56. Rooke, R., Parniak, M. A., Tremblay, M., Soudeyns, H., Li, X. G., Gao, Q. et al. (1991). Biological comparisons of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrobial Agents and Chemotherapy 35, 988-91.
57. Dimitrov, D. H., Hollinger, F. B., Baker, C. J., Kline, M. W., Doyle, M., Bremer, J. W. et al. (1993). Study of human immunodeficiency virus resistance to 2′3′-dideoxyinosine and zidovudine in sequential isolates from pediatric patients on long-term therapy. Journal of Infectious Diseases 167, 818-23.
58. Japour, A. J., Chatis, P. A., Eigenrauch, H. A. & Crumpacker, C. S. (1991). Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA-RNA hybridization. Proceedings of the National Academy of Sciences of the USA 88, 3092-6.
59. Mayers, D. L., Japour, A. J., Arduino, J.-M., Hammer, S. M., Reichman, R., Wagner, K. F. et al. (1994). Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrobial Agents and Chemotherapy 38, 307-14.
60. Larder, B. A. (1995). Viral resistance and the selection of anti retroviral combinations. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 10, Suppl. 1, 528-533.
61. Richman, D. D. (1993). Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrobial Agents and Chemotherapy 37, 1207-13.
62. Shirasaka, T., Yarchoan, R., O'Brien, M. C., Husson, R. N., Anderson, B. D., Kojima, E. et al. (1993). Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine and dideoxyinosine: an in vitro comparative study. Proceedings of the National Academy of Sciences of the USA 90, 562-6.
63. Richman, D. D., Meng, T. C., Specter, S. A., Fischl, M. A., Resnick, L. & Lai, S. (1994). Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndrome 7, 135-8.
64. Gao, W. Y., Agbaria, R., Driscoll, J. S. & Mitsuya, H. (1994). Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′3′-dideoxynucleoside analogs in resting and activated human cells. Journal of Biological Chemistry 269, 12633-8.
65. Conway, B., Ko, D. S., Marshall, L., Filion, L. G., Diaz-Mitoma, F. J. & Cameron, D. W. (1993). Evaluation of ddC susceptibility in patients on AZT or ddl. In Proceedings of the Second International HIV Drug Resistance Workshop, Noordwijk 1993.
66. Kozal, M. J., Kroodsma, K., Winters, M. A., Shafer, R. W., Efron, B., Katzenstein, D. A. et al. (1994). Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Annals of Internal Medicine 121, 263-8.
67. Gu, Z., Gao, Q., Fang, H., Salomon, H., Parniak, M. A., Goldberg, E. et al. (1994). Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy 38, 275-81.
68. Fitzgibbon, J. E., Howell, R. M., Haberzettl, C. A., Sperber, S. J., Gocke, D. J. & Dubin, D. T. (1992). Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrobial Agents and Chemotherapy 36, 153-7.
69. Craig, C. & Moyle, G. (1997). The development of resistance of HIV-1 to zalcitabine. AIDS 11, 271-9.
70. Schooley, R. T., Ramirez-Ronda, C., Lange, J. M. A., Cooper, D. A., Lavelle J., Lefkowitz, L. et al. (1996). Virologic and immmunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine alone. Journal of Infectious Diseases 173, 1354-66.
71. Shafer, R. W., Iversen, A. K. N., Winters, M. A., Aguiniga, E., Katzenstein, D. A. & Merigan, T. C. (1995). Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. Journal of Infectious Diseases 172, 70-8.
72. Fitzgibbon, J. E., Farnham, A. E., Sperber, S. J., Kim, H. & Dubin, D. T. (1993). Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. Journal of Virology 67, 7271-5.
73. Shafer, R. W., Kozal, M. J., Winters, M. A., Iversen, A. K., Katzenstein, D. A., Ragni, M. V. et al. (1994). Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. Journal of Infectious Diseases 169, 722-9.
74. Shirasaka, T., Kavlick, M. F., Ueno, T., Gao, W. Y., Kojima, E., Alcaide, M. L. et al. (1995). Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxy-nucleosides. Proceedings of the National Academy of Sciences of the USA 92, 2398-402.
75. Shafer, R. W., Winters, M. A., Iversen, A. K. N. & Merigan, T. C. (1996). Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy 40, 2887-90.
76. Schmit, J. C., Cogniaux, J., Hermans, P., Van Vaeck, C., Sprecher, S., Van Remoortel, B. et al. (1996). Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. Journal of Infectious Diseases 174, 962-8.
77. Gao, Q., Gu, Z. X., Parniak, M. A., Cameron, J., Cammack, N., Boucher, C. et al. (1993). The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-)enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy 37, 1390-2.
78. Schinazi, R. F., Lloyd, R. M., Nguyen, M.-H., Cannon, D. L., McMillan, A., Ilksoy, N. et al. (1993). Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents and Chemotherapy 37, 875-81.
79. Wainberg, M. A., Salomon, H., Gu, Z., Montaner, J. S., Cooley, T. P., McCaffrey, R. et al. (1995). Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9, 351-7.
80. Nijhuis, M., de Jong, D., van Leeuwen, R., de Groot, T., Keulen, W., Schuurman, R. et al. (1995). The rise in HIV-1 RNA viral load during 3TC/AZT combination therapy is associated with the selection of viruses resistant to both 3TC and AZT. In Proceedings of the 4th International HIV Drug-resistance Workshop, Sardinia, 1995. Abstract 52.
81. Kuritzkes, D. R., Quinn, J. B., Benoit, S. L., Shugarts D. L, Griffin, A., Bakhtiari, M. et al. (1996). Drug resistance and virologic response to NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10, 975-81.
82. Harrigan, P. R., Bloor, S., Kinghorn, I., Lamivudine European HIV working group & Larder, B. A. (1995). Virological response to AZT/3TC combination therapy in AZT experienced patients (Trial NUCB3002). In Proceedings of the 4th International HIV Drug-resistance Workshop, Sardinia, 1995. Abstract 54.
83. Bartlett, J. A., Benoit, S. L., Johnson, V. A., Quinn, J. B., Sepulveda G. E., Ehmann, W. C. et al. (1996). Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 125, 161-72.
84. Eron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B. et al. (1995). Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New England Journal of Medicine 333, 1662-9.
85. Katlama, C., Ingrand, D., Loveday, C., Clumeck, N., Mallolas, J., Staszewski, S. et al. (1996). Safety and efficacy of lamivudine/zidovudine combination therapy in antiretroviral-naive patients: a randomized controlled comparison with zidovudine monotherapy. Journal of the American Medical Association 276, 118-25.
86. Staszewski, S., Loveday, C., Picazo, J. J., Dellarnonica, P., Skinhoj, P., Johnson, M. A. et al. (1996). Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients: a randomized controlled comparison with zidovudine monotherapy. Journal of the American Medical Association 276, 111-7.
87. Moyle, G. J. (1996). Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Drugs 52, 168-85.
88. Goulden, M. G., Cammack, N., Hopewell, P. L., Penn, C. R. & Cameron, J. M. (1996). Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. AIDS 10, 101-2.
89. Kemp, S. D., Kohli, A. & Larder, B. A. (1995). Genotypic characterisation of an HIV-1 mutant co-resistant to AZT and 3TC. In Proceedings of the 4th International HIV Drug-resistance Workshop, Sardinia, 1995. Abstract 51.
90. 3). In Proceedings of the Fifth International Workshop on HIV Drug Resistance, Whistler, 1996. Abstract 58.
91. Caesar Coordinating Committee. (1997). Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 349, 1413-21.
92. Gu, Z., Gao, Q., Li, X., Parniak, M. A. & Wainberg, M. A. (1992). Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. Journal of Virology 66, 7128-35.
93. Gu, Z., Gao, Q., Fang, H., Parniak, M., Brenner, B. G. & Wainberg, M. A. (1994). Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 8, Suppl. 1, 166-9.
94. Lacey, S. F. & Larder, B. A. (1994). Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3-dideoxythymidine in cell culture. Antimicrobial Agents and Chemotherapy 38, 1428-32.
95. Lin, P.-F., Samanta, H., Rose, R. E., Patick, A. K., Trimble, J., Bechtold, C. M. et al. (1994). Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. Journal of Infectious Diseases 170, 1157-64.
96. Harrigan, P. R., Tisdale, M., Najera, I., Cousens, D., St Clair, M., Stone, C. et al. (1996). Antiretroviral activity and resistance to 1592U89, a novel HIV RT inhibitor. In Proceedings of the Fifth International Workshop on HIV Drug Resistance, Whistler, 1996. Abstract 16.
97. St Clair, M. H., Hartigan, P. M., Andrews, J. C., Vavro, C. L., Simberkoff, M. S. & Hamilton, J. D. (1993). Zidovudine resistance, syncytium-inducing phenotype and HIV disease progression in a case-control study. Journal of Acquired Immune Deficiency Syndrome 6, 891-7.
98. Richman, D. D., Guatelli, J. C., Grimes, J., Tsiatis, A. & Gingeras, T. R. (1991). Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. Journal of Infectious Diseases 164, 1075-81.
99. Gazzard, B. G. & Moyle, G. J.(1995). Individualisation of HIV therapy: the clinician's perspective. British Journal of Clinical Practice 49, 145-7.
100. Kozal, M. J., Shafer, R. W., Winters, M. A., Katzenstein, D. A. & Merigan, T. C. (1993). A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. Journal of Infectious Diseases 167, 526-32.
101. Ogino, M. T., Dankner, W. M. & Spector, S. A. (1993). Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. Journal of Pediatrics 123, 1-8.
102. Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P. J., Mo, H. M. et al. (1996). Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 2, 760-6.
103. Richman, D. D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S. A. et al. (1994). Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology 68, 1660-6.
104. Saag, M. S., Emini, E. A., Laskin, O. L., Douglas, J., Lapidus, W. I., Schleif, W. A. et al. (1993). A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase: L-697,661 working group. New England Journal of Medicine 329, 1065-72.
105. Tudor-Williams, G., St Clair, M. H., McKinney, R. E., Maha, M., Walter, E., Santacroce, S. et al. (1992). HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 339, 15-9.
106. Montaner, J. S. G., Singer, J., Scnechter, M. T., Raboud, J. M., Tsoukas, C., O'Shaughnessy, M. et al. (1993). Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the multicenter Canadian AZT trial. AIDS 7, 189-96.
107. Principi, N., Marchisio, P., De Pasquale, M., Massironi, E., Tornaghi, R. & Vago, R. (1994). HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine. AIDS Research Human Retroviruses 10, 721-6.
108. Tremblay, M., Rooke, R. & Wainberg, M. A. (1992). Zidovudine-resistant and -sensitive HIV-1 isolates from patients on drug therapy: in vitro studies evaluating level of replication-competent viruses and cytopathogenicity. AIDS 6, 1445-9.
109. Caliendo, A. M., Savara, A., An, D., DeVore, K., Kaplan, J. C. & D'Aquila, R. T. (1996). Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. Journal of Virology 70, 2146-53.
110. Holodniy, M., Katzenstein, D., Mole, L., Winters, M. & Merigan, T. (1996). Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-synctium-inducing phenotype. Journal of Infectious Diseases 174, 854-7.
111. Moyle, G. & Gazzard, B. (1996). Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 51, 701-12.
112. Perrin, L., Yerly, S., Rakik, A., Kinloch, S. & Hirschl, B. (1995). Transmission of 215 mutants in primary HIV infection and analysis after 6 months of ZDV. In Proceedings of the 4th International HIV Drug-resistance Workshop, Sardinia, 1995. Abstract 21.
113. Harzic, M., Patey, O., Ferchal, F., Sageat, P. & Brun-Vezinet, F. (1995). AZT resistance mutations in virus from patients with recent HIV infection. In Proceedings of the 4th International HIV Drug-resistance Workshop, Sardinia, 1995. Abstract 26.
114. Garcia-Lerma, G., Soriano, V., Gomaz-Cano, M., Bravo, R., Mas, A., del Romero, J. et al. (1996). Prevalence of zidovudine-resistant HIV-1 among rapid progressors. AIDS 10, 1292-3.
115. Kojima, E., Shirasaka, T., Anderson, B. D., Chokekijchai, S., Steinberg, S. M., Broder, S. et al. (1995). Human immunodeficiency virus type 1 (HIV-1) viraemia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine or didanosine therapy. Journal of Infectious Diseases 171, 1152-8.
116. Larder, B. A., Kellam, P. & Kemp, S. D. (1993). Convergent combination therapy can select viable multidrug resistant HIV-1 in vitro. Nature 365, 451-3.